Melissa Rhodes, PhD, DABT

Chief Development Officer

Melissa Rhodes is the Chief Development Officer at Kriya Therapeutics. Dr. Rhodes joins us from Aerami Therapeutics, a company focused on inhaled biologic therapies where she was the Chief Development Officer. Prior to Aerami, Dr. Rhodes was the Chief Development Officer at Altavant Sciences, a respiratory rare disease company. Dr. Rhodes also served as Senior Vice President at Roivant Sciences, where she built and led a team of scientists conducting nonclinical research for multiple Roivant subsidiary companies. She spent almost ten years in R&D at GlaxoSmithKline. Dr. Rhodes started her career in drug development at an oncology-focused biotech university spin-out.

Dr. Rhodes received her PhD in pharmacology and toxicology from Duke University Medical Center. Dr. Rhodes completed a postdoctoral fellowship at the National Toxicology Program at the National Institute of Environmental Health Sciences, and is a diplomate of the American Board of Toxicology.